BR112014032142A2 - composto, composição farmacêutica, e, métodos de tratamento de um distúrbio proliferativo e de leucemia mielóide aguda - Google Patents
composto, composição farmacêutica, e, métodos de tratamento de um distúrbio proliferativo e de leucemia mielóide agudaInfo
- Publication number
- BR112014032142A2 BR112014032142A2 BR112014032142A BR112014032142A BR112014032142A2 BR 112014032142 A2 BR112014032142 A2 BR 112014032142A2 BR 112014032142 A BR112014032142 A BR 112014032142A BR 112014032142 A BR112014032142 A BR 112014032142A BR 112014032142 A2 BR112014032142 A2 BR 112014032142A2
- Authority
- BR
- Brazil
- Prior art keywords
- treating
- compound
- methods
- pharmaceutical composition
- myeloid leukemia
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/06—Peri-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
1 / 1 resumo âcomposto, composiãão farmacãutica, e, mãtodos de tratamento de um distãrbio proliferativo e de leucemia mielãide agudaâ a presente invenã§ã£o refere-se a compostos da fã³rmula i: i em que r e r sã£o como aqui definidos, ou um sal ou solvato 1 2 farmaceuticamente aceitã¡vel dos mesmos. os compostos da fã³rmula i sã£o inibidores de aurora quinase e/ou de flt3. a presente invenã§ã£o tambã©m se refere a processos para a preparaã§ã£o destes compostos, a composiã§ãµes farmacãªuticas que os compreendam, e a seu uso no tratamento de distãºrbios proliferativos, tais que o cã¢ncer, assim como outras doenã§as ou condiã§ãµes, nas quais a atividade de aurora quinase e/ou de flt3 estã¡ implicada.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1211021.9A GB201211021D0 (en) | 2012-06-21 | 2012-06-21 | Pharmaceutically active compounds |
| GB1211021.9 | 2012-06-21 | ||
| PCT/GB2013/051633 WO2013190319A1 (en) | 2012-06-21 | 2013-06-21 | Pharmaceutically active compounds |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| BR112014032142A2 true BR112014032142A2 (pt) | 2017-06-27 |
| BR112014032142B1 BR112014032142B1 (pt) | 2022-03-03 |
Family
ID=46641296
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112014032142-6A BR112014032142B1 (pt) | 2012-06-21 | 2013-06-21 | Composto e, composição farmacêutica |
Country Status (22)
| Country | Link |
|---|---|
| US (1) | US9447092B2 (pt) |
| EP (1) | EP2864328B8 (pt) |
| JP (1) | JP6159397B2 (pt) |
| CN (1) | CN104470922B (pt) |
| AU (1) | AU2013279040B2 (pt) |
| BR (1) | BR112014032142B1 (pt) |
| CA (1) | CA2876357C (pt) |
| CY (1) | CY1120608T1 (pt) |
| DK (1) | DK2864328T3 (pt) |
| ES (1) | ES2660159T3 (pt) |
| GB (1) | GB201211021D0 (pt) |
| HR (1) | HRP20180386T1 (pt) |
| HU (1) | HUE036048T2 (pt) |
| IN (1) | IN2015MN00045A (pt) |
| LT (1) | LT2864328T (pt) |
| NO (1) | NO2864328T3 (pt) |
| PL (1) | PL2864328T3 (pt) |
| PT (1) | PT2864328T (pt) |
| RS (1) | RS56996B1 (pt) |
| RU (1) | RU2654942C2 (pt) |
| SI (1) | SI2864328T1 (pt) |
| WO (1) | WO2013190319A1 (pt) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201522532D0 (en) * | 2015-12-21 | 2016-02-03 | Cancer Rec Tech Ltd | Novel pyrrolo[3,2-c]pyridine-6-amino derivatives |
| JP6591036B2 (ja) | 2016-02-26 | 2019-10-16 | 公益財団法人がん研究会 | Ｈｐ１の機能に着目した抗癌剤のスクリーニング方法及び評価系 |
| GB2596038B (en) * | 2020-03-04 | 2022-12-14 | Ellipses Pharma Ltd | Salts and polymorphic forms of (6-chloro-7-(4-(4-chlorobenzyl)piperazin-1-yl)-2-(1,3-dimethyl-1H-pyrazol-4-yl)-3H-imidazo[4,5-B]pyridine) |
| GB2592622B (en) | 2020-03-04 | 2022-08-03 | Ellipses Pharma Ltd | Formulations of a dual aurora kinase/FLT3 inhibitor |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9624482D0 (en) | 1995-12-18 | 1997-01-15 | Zeneca Phaema S A | Chemical compounds |
| BR9707495A (pt) | 1996-02-13 | 1999-07-27 | Zeneca Ltd | Derivado de quinazolina processo para a preparação do mesmo composição farmacêutica e processo para a produç o de um efeito antiangiogênico e/ou de redução de permeabilidade vascular em um animal de sangue quente |
| KR100489174B1 (ko) | 1996-03-05 | 2005-09-30 | 제네카-파마 소시에떼아노님 | 4-아닐리노퀴나졸린유도체 |
| GB9718972D0 (en) | 1996-09-25 | 1997-11-12 | Zeneca Ltd | Chemical compounds |
| GB9714249D0 (en) | 1997-07-08 | 1997-09-10 | Angiogene Pharm Ltd | Vascular damaging agents |
| GB9900334D0 (en) | 1999-01-07 | 1999-02-24 | Angiogene Pharm Ltd | Tricylic vascular damaging agents |
| GB9900752D0 (en) | 1999-01-15 | 1999-03-03 | Angiogene Pharm Ltd | Benzimidazole vascular damaging agents |
| IL152682A0 (en) | 2000-05-31 | 2003-06-24 | Astrazeneca Ab | Indole derivatives with vascular damaging activity |
| UA73993C2 (uk) | 2000-06-06 | 2005-10-17 | Астразенека Аб | Хіназолінові похідні для лікування пухлин та фармацевтична композиція |
| US20050277627A1 (en) | 2000-07-07 | 2005-12-15 | Arnould Jean C | Colchinol derivatives as vascular damaging agents |
| KR20030022264A (ko) | 2000-07-07 | 2003-03-15 | 앤지오젠 파마슈티칼스 리미티드 | 신생 혈관 형성 억제제인 콜치놀 유도체 |
| US7064215B2 (en) * | 2001-07-03 | 2006-06-20 | Chiron Corporation | Indazole benzimidazole compounds |
| TWI372050B (en) * | 2003-07-03 | 2012-09-11 | Astex Therapeutics Ltd | (morpholin-4-ylmethyl-1h-benzimidazol-2-yl)-1h-pyrazoles |
| CN102127078A (zh) * | 2005-07-14 | 2011-07-20 | 安斯泰来制药株式会社 | Janus激酶3的杂环类抑制剂 |
| WO2007072017A2 (en) * | 2005-12-22 | 2007-06-28 | The Institute Of Cancer Research | Enzyme inhibitors |
| CN101616920A (zh) * | 2007-01-30 | 2009-12-30 | 比奥根艾迪克Ma公司 | 1-H-吡唑并(3,4b)嘧啶衍生物及其作为有丝分裂激酶调节剂的用途 |
| WO2009001021A1 (en) * | 2007-06-26 | 2008-12-31 | Chroma Therapeutics Ltd. | Imidazopyridine derivatives useful as enzyme inhibitors for the treatment of cell proliferative and autoimmune diseases |
| CN102143746A (zh) * | 2008-07-03 | 2011-08-03 | 埃克塞利希斯股份有限公司 | Cdk 调节剂 |
| TWI617560B (zh) * | 2010-09-14 | 2018-03-11 | 伊塞利克斯公司 | PI3Kδ 抑制劑以及其應用和生產方法 |
-
2012
- 2012-06-21 GB GBGB1211021.9A patent/GB201211021D0/en not_active Ceased
-
2013
- 2013-06-21 US US14/409,042 patent/US9447092B2/en active Active
- 2013-06-21 PL PL13731470T patent/PL2864328T3/pl unknown
- 2013-06-21 HU HUE13731470A patent/HUE036048T2/hu unknown
- 2013-06-21 RU RU2015101702A patent/RU2654942C2/ru active
- 2013-06-21 JP JP2015517858A patent/JP6159397B2/ja active Active
- 2013-06-21 ES ES13731470.4T patent/ES2660159T3/es active Active
- 2013-06-21 RS RS20180267A patent/RS56996B1/sr unknown
- 2013-06-21 NO NO13731470A patent/NO2864328T3/no unknown
- 2013-06-21 EP EP13731470.4A patent/EP2864328B8/en active Active
- 2013-06-21 BR BR112014032142-6A patent/BR112014032142B1/pt active IP Right Grant
- 2013-06-21 CA CA2876357A patent/CA2876357C/en active Active
- 2013-06-21 DK DK13731470.4T patent/DK2864328T3/en active
- 2013-06-21 PT PT137314704T patent/PT2864328T/pt unknown
- 2013-06-21 IN IN45MUN2015 patent/IN2015MN00045A/en unknown
- 2013-06-21 WO PCT/GB2013/051633 patent/WO2013190319A1/en active Application Filing
- 2013-06-21 SI SI201330965T patent/SI2864328T1/en unknown
- 2013-06-21 CN CN201380032901.2A patent/CN104470922B/zh active Active
- 2013-06-21 AU AU2013279040A patent/AU2013279040B2/en active Active
- 2013-06-21 LT LTEP13731470.4T patent/LT2864328T/lt unknown
-
2018
- 2018-03-05 HR HRP20180386TT patent/HRP20180386T1/hr unknown
- 2018-03-06 CY CY181100275T patent/CY1120608T1/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP2864328B1 (en) | 2017-12-06 |
| CA2876357A1 (en) | 2013-12-27 |
| JP2015520222A (ja) | 2015-07-16 |
| WO2013190319A1 (en) | 2013-12-27 |
| PT2864328T (pt) | 2018-03-12 |
| BR112014032142B1 (pt) | 2022-03-03 |
| CN104470922A (zh) | 2015-03-25 |
| HRP20180386T1 (hr) | 2018-04-20 |
| CY1120608T1 (el) | 2019-12-11 |
| AU2013279040B2 (en) | 2017-11-16 |
| EP2864328B8 (en) | 2018-01-24 |
| EP2864328A1 (en) | 2015-04-29 |
| RU2654942C2 (ru) | 2018-05-25 |
| RS56996B1 (sr) | 2018-05-31 |
| US20150266868A1 (en) | 2015-09-24 |
| IN2015MN00045A (pt) | 2015-10-16 |
| AU2013279040A1 (en) | 2015-01-29 |
| US9447092B2 (en) | 2016-09-20 |
| JP6159397B2 (ja) | 2017-07-05 |
| LT2864328T (lt) | 2018-04-10 |
| SI2864328T1 (en) | 2018-04-30 |
| CA2876357C (en) | 2020-07-14 |
| RU2015101702A (ru) | 2016-08-10 |
| DK2864328T3 (en) | 2018-03-12 |
| ES2660159T3 (es) | 2018-03-21 |
| HUE036048T2 (hu) | 2018-06-28 |
| GB201211021D0 (en) | 2012-08-01 |
| CN104470922B (zh) | 2016-08-24 |
| PL2864328T3 (pl) | 2018-06-29 |
| NO2864328T3 (pt) | 2018-05-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112016001954A2 (pt) | composto, composição farmacêutica, e, método para tratar uma doença ou condição | |
| BR112015032623A2 (pt) | composto, composição farmacêutica, métodos para tratar doenças e condições, e para degradar o receptor de estrogênio, usos de um composto e de uma combinação, e, combinação | |
| BR112015013611A2 (pt) | composto, e, composição farmacêutica | |
| BR112015023948A2 (pt) | composto de fórmula (i), composição farmacêutica, método para o tratamento e/ou prevenção de uma doença proliferativa e para a inibição ou a diferenciação do crescimento de uma célula tronco do câncer | |
| BR112014029851A2 (pt) | composto, inibidores da atividade da enzima ros1 quinase e da enzima ntrk quinase, composição farmacêutica, agente antitumor, agente terapêutico para um tumor, método para tratamento de um tumor, e, agente para tratamento de um tumor | |
| BR112015026023A2 (pt) | derivados de 2- aminopirido[4,3-d]pirimidin-5-ona e seu uso como inibidores de wee-1 | |
| BR112014026643A8 (pt) | derivados de imidazotiadiazol e imidazopirazina como inibidores de receptor 4 ativado por protease (par4) para o tratamento de agregação de plaqueta, seus usos e composição farmacêutica | |
| EA201490891A1 (ru) | Пиридопиразины, обладающие противораковой активностью через ингибирование fgfr киназ | |
| BR112019006047A2 (pt) | compostos, um ou dois ou mais compostos, sal farmaceuticamente aceitável, sal metanossulfonato, inibidor de quinase ret, medicamento, usos do composto e de um composto, métodos para tratar ou prevenir câncer e para tratar ou prevenir câncer em um indivíduo, e, composição farmacêutica | |
| BR112015028879A8 (pt) | compostos derivados heterocíclicos, composição farmacêutica compreendendo os referidos compostos e usos dos mesmos | |
| BR112018005932A2 (pt) | inibidores de isoindolinona da interação de mdm2-p53 que têm atividade anticâncer | |
| BR112014022106A2 (pt) | derivados macrocíclicos para o tratamento de doenças | |
| BR112015028501A2 (pt) | derivados de bipirazol como inibidores de jak | |
| BR112015001695A2 (pt) | compostos de heteroarila e heterociclo, composições e métodos | |
| BR112015012454A8 (pt) | compostos inibidores de atr quinase, seu uso, composição farmacêutica compreendendo os mesmos, seus intermediários e método de preparação | |
| BR112014013661A8 (pt) | derivados de nucleosídeos 2,4-difluoro-2-metil substituídos como inibidores de replicação de hcv-rna | |
| BR112012008073A2 (pt) | compostos heterocíclicos como inibidores de janus quinase | |
| BR112013001088A2 (pt) | "derivados substituídos como inibidores a quinase de imidazoquinolina" | |
| BR112018071408A2 (pt) | “composto inibidor de rip2 quinase, composição farmacêutica, usos de um composto e de uma combinação, e, combinação | |
| EA201101583A1 (ru) | Ингибиторы pi3 киназы или mtor | |
| EA201692506A3 (ru) | Ингибиторы репликации вирусов гриппа | |
| BR112014000792A2 (pt) | compostos de piperidinila para uso como inibidores da tanquirase | |
| BR112017004741A2 (pt) | compostos e composições como inibidores da raf quinase | |
| UY34955A (es) | 4-metil-2,3,5,9,9b-pentaaza-ciclopenta[a]naftalenos | |
| BR112014029708A2 (pt) | composto de pirrolo[2,1-f][1,2,4]triazina, método de preparação de compostos de pirrolo[2,1-f][1,2,4]triazina e uso do composto de pirrolo[2,1-f][1,2,4]triazina |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
| B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
| B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
| B06I | Publication of requirement cancelled [chapter 6.9 patent gazette] |
Free format text: ANULADA A PUBLICACAO CODIGO 6.6.1 NA RPI NO 2462 DE 13/03/2018 POR TER SIDO INDEVIDA. |
|
| B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] |
Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI |
|
| B06U | Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette] | ||
| B25A | Requested transfer of rights approved |
Owner name: THE INSTITUTE OF CANCER RESEARCH: ROYAL CANCER HOSPITAL (GB) |
|
| B09A | Decision: intention to grant [chapter 9.1 patent gazette] | ||
| B16A | Patent or certificate of addition of invention granted [chapter 16.1 patent gazette] |
Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 21/06/2013, OBSERVADAS AS CONDICOES LEGAIS. |